TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01515891
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 µCi (3.33 MBq) \[14C\]-labeled of 100 mg BIA 9-1067 (single-dose).
Study: NCT03692663
Drug: TABP EIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 0.5, 10, and 30 million TABP EIC will be iv administered at D0, D7, and D14.
Study: NCT00060346
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given at a dosage of 750 mg/m² intravenously on day 1 of each cycle (1 cycle =21 days) for 6 cycles. Dose is based on surface area calculated based on actual body weight.~The drug should be administered as a rapid IV infusion over 5 to 30 minutes.
Study: NCT00060346
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be given intravenously at a dosage of 50 mg/m² on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Doxorubicin should be administered as a continuous infusion into tubing of a freely flowing intravenous line for 5 -15 minutes. Avoid extravasation.
Study: NCT00211263
Drug: mood stabilizer
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00272909
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous IV infusion over a period of up to 72 hours of placebo.
Study: NCT02955641
Drug: Nepafenac 0.1%
Normalized name: NEPAFENAC 0.1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: four drops a day for four days after LPI treatment
Study: NCT02920385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once daily together with semaglutide
Study: NCT00893724
Drug: Neutral pills with no medicinal effect
Normalized name: Phospha 250 Neutral Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral pills with no medicinal effect
Study: NCT00893724
Drug: Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine \[SR\] - 1 \[500mg\] tablet bid Tocopherol \[200IU\], Tocotrienol \[10mg\], CoQ10 \[50mg\] combination capsule bid Sustained Release Niacinamide 1 \[750mg\] tablet bid Vitamin C 1 \[1000mg\] sustained release tablet bid N-acetyl Cysteine 1 \[600mg\] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid Minocycline 1 \[50mg\] tablet qd
Study: NCT01605162
Drug: E7016
Normalized name: Erdafitinib
DrugBank: Erdafitinib (DB12147)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E7016 capsules will be administered in the morning after at least a 2-hour fast. Subjects will be instructed not to eat or drink anything except water in the 2 hours prior and 2 hours after drug administration. Subjects will record the time at which they ate.~For the Single-Dose PK Period, 320 mg of E7016 will be administered once on Day -2. For the Multiple-Dose Treatment Cycle(s), 320 mg E7016 will be administered QD on Days 1 through 7 of each 28-day cycle.
Study: NCT02820311
Drug: Placebo for TD-4208
Approvals — FDA: no, EMA: no, PMDA: no
Description: via nebulizer
Study: NCT04621370
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine is a non-cytotoxic pre-cursor of cytotoxic 5-fluorouracil and delivered in oral form. It is given concomitantly with long course radiation treatment on days of radiotherapy only. The dose is 825mg/m2 and this is delivered twice daily.
Study: NCT00823095
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied gaseous nitric oxide at 8 to 10 parts per million, for 8 hours each night for 14 nights.
Study: NCT04527107
Drug: THR-149 0.13mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 intravitreal injections of THR-149 0.13mg (selected dose level), 1 month apart, followed after 1 month by a sham (pretend) injection
Study: NCT00811135
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg/m2 bid po on days 1-14 of each 3-week cycle
Study: NCT01311791
Drug: Standard medical therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: as defined per protocol
Study: NCT00428974
Drug: CF101 1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF101 1 mg q12 hours for 12 weeks
Study: NCT00428974
Drug: CF101 4mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF101 4 mg q12 hours for 12 weeks
Study: NCT00428974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets q12 hours for 12 weeks
Study: NCT01714427
Drug: Sterile isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: two doses of 100 ml physiologic saline solution will be administered intravenously prior to LPS instillation.
Study: NCT00392665
Drug: Sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally twice a day
Study: NCT00840216
Drug: BIAXIN® XL 500 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 500 mg
Study: NCT02859311
Drug: Withdrawal of therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of heart failure therapies (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists and loop diuretics)
Study: NCT00907907
Drug: CellCept® Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: CellCept® Tablets, 500 mg
Study: NCT01742702
Drug: Salbutamol 400 µg (single dose, no longer given since January 2017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: From the beginning of the study until the end of year 2016 a 400 µg dose of inhaled salbutamol was given to examine the associated acute haemodynamic effects (recordings completed).
Study: NCT02868697
Drug: TauroLock U 25000
Approvals — FDA: no, EMA: no, PMDA: no
Description: taurolidine citrate, 4% citrate /25000 IU unit urokinase (TauroLock U25000
Study: NCT02868697
Drug: (TauroLock Hep500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.35% taurolidine citrate (2H-1,2,4-thiadiazine-4,4'-methylenebis\[tetrahydro-1,1,1',1'-tetraoxide\], 4% citrate and 500 IU/ml heparin (TauroLock Hep500) (TauroPharmGmbH
Study: NCT02329769
Drug: PRO044 SC 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02329769
Drug: PRO044 IV 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02329769
Drug: PRO044 IV 9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04857177
Drug: Lucentis®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lucentis® (ranibizumab) 0.5mg via intravitreal injection every one month during the loading phase, and intervals of one month based on criteria during the PRN phase.
Study: NCT00919503
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01259791
Drug: Individual-specific statin causing myopathy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual-specific statin causing myopathy vs. placebo
Study: NCT01259791
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03902548
Drug: [18F]P16-129
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of \< 10 mCi \[18F\]P16-129 followed by PET/CT scanning
Study: NCT00375648
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02305355
Drug: Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03322631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT02917889
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Volunteers will consume 300 mg of caffeine in pills fifteen minutes before treadmill aerobic exercise.
Study: NCT02917889
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteers will consume 300 mg of placebo in pills fifteen minutes before treadmill aerobic exercise.
Study: NCT05930262
Drug: Conventional drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics were selected based on drug sensitivity test results. Patients with body temperature \> 38.5℃ were treated with physical cooling and antipyretic drugs. In patients whose sputum was thick and difficult to cough up, nebulization and inhalation therapy was given, as well as effective coughing and patting the back to expel phlegm were guided.
Study: NCT04283695
Drug: GX-I7 or [14C] GX-I7
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM GX-I7 or IV/IM microdose of GX-I7
Study: NCT01515657
Drug: Enteric-coated aspirin caplets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg aspirin; once per day for 3 days
Study: NCT01297270
Drug: BI201335
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD BI 201335
Study: NCT01297270
Drug: PegIFN/RBV
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01297270
Drug: BI201335
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD (once daily) BI 201335
Study: NCT01297270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01052311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once daily
Study: NCT01052311
Drug: Tredaptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tredaptive 1 g \[Laropiprant 20 mg(LRP; Merck \& Co., Inc, Whitehouse Station, NJ, USA) and 1 g of extended-release niacin\]from day 1 to 30 once daily. From day 31 to 90, the same but 2 g instead of 1 g of extended-release niacin.
Study: NCT03988335
Drug: RIST4721
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIST4721 oral solution
Study: NCT03988335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution
Study: NCT01959074
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: aceclofenac 100mg on demand
Study: NCT02378961
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg FDC tablet administered orally once daily with food
Study: NCT01281566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
Study: NCT00091715
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo for 6 months followed by an open-label period
Study: NCT00858754
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01127724
Drug: vitamin B12 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
Study: NCT02918019
Drug: MSTT1041A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSTT1041A will be administered as subcutaneous injections.
Study: NCT02918019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched with MSTT1041A.
Study: NCT00147563
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03807037
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to be administered orally at 1 capsule, twice daily
Study: NCT02875639
Drug: Yiqi prescription
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02875639
Drug: Huoxue prescription
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02875639
Drug: Buyang huanwu decoction
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02875639
Drug: QISHEN YIQI DRIPPING PILLS
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02875639
Drug: Placebo 1
Normalized name: placebo 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.
Study: NCT02875639
Drug: Placebo 2
Normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2：a drug which imitated Buyang huanwu decoction,but do not have active ingredient,just have the excipient.
Study: NCT00746395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT03793712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral dose, tablets. Once daily. 12 weeks.
Study: NCT01018979
Drug: TG-0054 (2.24 mg/kg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
Study: NCT01018979
Drug: TG-0054 (3.14 mg/kg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
Study: NCT00498173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets dosages: 5 mg, 10 mg, 25 mg, 40 mg.
Study: NCT01681264
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00720109
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00720109
Drug: Hydrocortisone Sodium Succinate
Normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IT
Study: NCT00720109
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT00720109
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00720109
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT, PO, or IV
Study: NCT00042861
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00042861
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04031651
Drug: Pudilan Xiaoyan Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the respiratory and emergency departments of the hospitals under surveillance, the medication of Pudilan Xiaoyan Oral Liquid is observed for those aged 18-80 years who strictly follow the prescription of the instructions.
Study: NCT02199873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03733444
Drug: GLPG1690
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1690, film-coated tablets for oral use.
Study: NCT03733444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, film-coated tablets for oral use.
Study: NCT00556322
Drug: Alimta or Taxotere
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg/m2 / 3 weeks (Alimta) or 75mg/m2 / 3 weeks (Taxotere)
Study: NCT01637272
Drug: SOM230
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide (SOM230) sc injection was provided as solution for injection in individual 1-point-cut 1 mL ampule, containing nominally 200 μg of pasireotide (as free base). Doses: 50, 100, 150 and 200 μg. Pasireotide im LAR depot injection was provided as micro particles powder in vials containing nominally 10, 20, 40 \& 60 mg of pasireotide (as free base) \& solvent for suspension for injection in ampules for the reconstitution of the LAR micro particles. Doses: 10, 20, 30, 40 or 60 mg
Study: NCT01899755
Drug: GSK2800528, solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug will be administered at 3 different dose levels by subcutaneous injection.
Study: NCT01899755
Drug: Placebo (0.9% w/v Sodium Chloride), solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of. 0.8 mL solution will be administered
Study: NCT03664063
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment with Azithromycin single dose - weight based dosing max 2gm
Study: NCT03978000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water
Study: NCT02018731
Drug: Metformin and Metformin & L-Citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02018731
Drug: L-Citrulline and Metformin & L-Citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03024060
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
Study: NCT00047138
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00047138
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003980
Drug: BIBX 1382
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00179582
Drug: VSL#3
Normalized name: VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02189850
Drug: BLI800 - Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLI800 oral solution
Study: NCT01326494
Drug: Arm 1 Oral Cortico Steroids
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.~Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )
Study: NCT02423915
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg by vein on Day -8.
Study: NCT02250781
Drug: Oral ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01537757
Drug: MK-8931
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, administered as oral capsules
Study: NCT02216461
Drug: High dose of BIBW 2948 BS for oral inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02216461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03900871
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (aspirin), also known as acetylsalicylic acid (acetylsalicylic acid), is a salicylic acid drug commonly used as a painkiller, antipyretic and anti-inflammatory drug. There is growing evidence that aspirin has a preventive effect on certain cancers, especially gastrointestinal cancers, and that taking aspirin every day can reduce the risk of colon cancer, and in vitro experiments have also shown that aspirin inhibits the growth of a variety of cancer cells and induces apoptosis.
Study: NCT05080010
Drug: 3 cycles chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
Study: NCT02803944
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02735369
Drug: 2% OC-10X
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% OC-10X
Study: NCT02735369
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02065752
Drug: CANA/MET XR FDC, Formulation 1, 50 mg/500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
Study: NCT02065752
Drug: CANA/MET XR FDC, Formulation 2, 50 mg/500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
Study: NCT03705728
Drug: Remifentanil automatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil will be automatically administered according to the EasyTIVA device algorythm to maintain the BIS value within the 40-60 interval
Study: NCT03705728
Drug: Remifentanil manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil will be manually administered to maintain the BIS value within the 40-60 interval
Study: NCT00003642
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01358864
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to BI201335 for 24 weeks
Study: NCT03848507
Drug: albumin 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 20% albumin during cystectomy
Study: NCT00644787
Drug: Fentanyl 1-day transdermal patch (Titration Phase)
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14.
Study: NCT00644787
Drug: Fentanyl 1-day transdermal patch (Double Blind Phase)
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
Study: NCT00644787
Drug: Fentanyl 3-day transdermal patch (Double Blind Phase)
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
Study: NCT00644787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
Study: NCT00644787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
Study: NCT04901208
Drug: Placebo pod
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine-free pods administered to individuals who use Juul